These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36015360)

  • 1. Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone.
    Rüdesheim S; Selzer D; Mürdter T; Igel S; Kerb R; Schwab M; Lehr T
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions.
    Rüdesheim S; Wojtyniak JG; Selzer D; Hanke N; Mahfoud F; Schwab M; Lehr T
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33322314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups.
    Rüdesheim S; Selzer D; Fuhr U; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):494-511. PubMed ID: 35257505
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Shimizu M; Uehara S; Ohyama K; Nishimura H; Tanaka Y; Saito Y; Suemizu H; Yoshida S; Yamazaki H
    Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37879849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
    Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
    Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Drug-Drug-Gene Interaction Scenarios of (
    Kovar C; Kovar L; Rüdesheim S; Selzer D; Ganchev B; Kröner P; Igel S; Kerb R; Schaeffeler E; Mürdter TE; Schwab M; Lehr T
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
    Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
    Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
    Locatelli I; Kastelic M; Koprivsek J; Kores-Plesnicar B; Mrhar A; Dolzan V; Grabnar I
    Eur J Pharm Sci; 2010 Oct; 41(2):289-98. PubMed ID: 20599499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.
    Hongkaew Y; Gaedigk A; Wilffert B; Ngamsamut N; Kittitharaphan W; Limsila P; Sukasem C
    Sci Rep; 2021 Feb; 11(1):4158. PubMed ID: 33603025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
    Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
    Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Cui Y; Yan H; Su Y; Wang L; Lu T; Zhang D; Yue W
    Front Pharmacol; 2020; 11():936. PubMed ID: 32848719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
    Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
    Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions.
    Berecz R; Dorado P; De La Rubia A; Cáceres MC; Degrell I; LLerena A
    Curr Drug Targets; 2004 Aug; 5(6):573-9. PubMed ID: 15270204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.